February 7th 2025
GLP-1 RA use was linked to a reduced risk of alcohol-associated liver disease, lower rates of hepatic decompensation, and improved survival.
Improving the Care Cascade: Early Intervention for Perinatal HCV, with Megan Rose Curtis, MD
March 15th 2024Curtis discusses findings from her recent health economic study about the cost-effectiveness of treating perinatal HCV earlier, a growing concern amid rising rates of HCV in reproductive-aged adults.
Crisis Point: Stigma Hinders Adoption of Hepatitis C-Positive Donor Kidneys
March 14th 2024To acknowledge World Kidney Day, our latest episode of Crisis Point focuses on the stigma surrounding the use of HCV-positive donor kidneys amid the ongoing organ shortage crisis, with the perspective of a pair of experts and an HCV donor kidney recipient.
Experts' Perspectives: How to Address a Lack of Diversity in Clinical Trials
March 1st 2024In the final part of our 3-part series, our panel of experts discuss what their fields and its leaders could do to make sure this lack of diversity in trials does not continue. These responses are highlighted in the following video and transcribed below.
Experts' Perspectives: How Lack of Trial Diversity Impacts Treatment Development
March 1st 2024In part 2 of our 3-part series on the impact of clinical trials lacking diversity, we are spotlighting responses to our second question, which addresses how the previously established lack of diversity in clinical trials has had a direct effect on the development and application of new therapies or devices in real-world settings.
Experts' Perspective: How a Historic Lack of Diversity Manifests in Real-World Care
March 1st 2024In part 1 of our 3-part series on the impact of clinical trials lacking diversity, we are spotlighting responses to our first question, which sought to encapsulate the perspectives of our group of experts on how a historic lack of diversity in clinical trials has manifested itself in today’s care of patients from diverse backgrounds.